Mirikizumab治疗溃疡性结肠炎的随机2期研究疗效与安全性
这项随机2期试验纳入中重度活动性溃疡性结肠炎患者,比较静脉安慰剂与mirikizumab 50 mg、200 mg(暴露驱动剂量)及600 mg(固定剂量)在第0、4、8周的诱导疗效。第12周临床缓解主要终点未达统计学显著,但临床应答率显著高于安慰剂;维持期皮下200 mg每4周或每12周均显示持久疗效。
要点
- 第12周临床缓解率:50 mg组15.9%(P=.066)、200 mg组22.6%(P=.004)、600 mg组11.5%(P=.142),安慰剂组4.8%。
- 第12周临床应答率:50 mg组41.3%(P=.014)、200 mg组59.7%(P<.001)、600 mg组49.2%(P=.001),安慰剂组20.6%。
- 第52周临床缓解率:皮下200 mg每4周组46.8%,每12周组37.0%。
核心结论
- Mirikizumab可在12周诱导临床应答,但主要终点临床缓解未达统计学显著。
- 需进一步研究确定诱导缓解的最佳剂量。
- 维持期皮下给药显示持久疗效。
研究设计与样本
- 随机2期试验,2016年1月至2017年9月从14个国家入组中重度活动性UC患者。
- 诱导期随机分组:静脉安慰剂(N=63)、mirikizumab 50 mg(N=63)、200 mg暴露驱动剂量(N=62)、600 mg固定剂量(N=61),第0、4、8周给药。
- 63%患者既往暴露于生物制剂。
- 第12周临床应答者随机接受皮下mirikizumab 200 mg每4周(N=47)或每12周(N=46)维持治疗。
主要发现
- 第12周临床缓解率:50 mg组15.9%(P=.066)、200 mg组22.6%(P=.004)、600 mg组11.5%(P=.142),安慰剂组4.8%。
- 主要终点未显著(600 mg组与安慰剂比较,P>.05)。
- 第12周临床应答率:50 mg组41.3%(P=.014)、200 mg组59.7%(P<.001)、600 mg组49.2%(P=.001),安慰剂组20.6%。
- 第52周临床缓解率:皮下200 mg每4周组46.8%,每12周组37.0%。
关键数值与推荐
- 主要终点为第12周临床缓解:直肠出血Mayo子评分0分、排便频率较基线下降1分、内镜子评分0或1分。
- 临床应答定义:9分Mayo评分较基线下降≥2分且≥35%,同时直肠出血子评分下降≥1分或直肠出血子评分0或1分。
临床怎么用
- Mirikizumab 200 mg暴露驱动剂量在诱导临床应答方面显示优于安慰剂的效果。
- 皮下200 mg每4周或每12周维持治疗均可维持临床缓解。
- 诱导期最佳剂量尚未确定,需进一步研究。
局限性
- 主要终点未达统计学显著,多重检验程序在600 mg组比较后终止。
- 样本量较小,为2期研究。
- 需额外研究确定诱导缓解的最佳剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients with UC. METHODS: We performed a trial of the efficacy and safety of mirikizumab in patients with moderate to severely active UC, enrolling patients from 14 countries from January 2016 through September 2017. Patients were randomly assigned to groups given intravenous placebo (N = 63), mirikizumab 50 mg (N = 63) or 200 mg (N = 62) with exposure-based dosing, or mirikizumab 600 mg with fixed dosing (N = 61) at weeks 0, 4, and 8. Of assigned patients, 63% had prior exposure to a biologic agent. Clinical responders (decrease in 9-point Mayo score, including ≥2 points and ≥35% from baseline with either a decrease of rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1) at week 12 who had received mirikizumab were randomly assigned to groups that received maintenance treatment with mirikizumab 200 mg subcutaneously every 4 weeks (N = 47) or every 12 weeks (N = 46). The primary endpoint was clinical remission (Mayo subscores of 0 for rectal bleeding, with 1-point decrease from baseline for stool frequency, and 0 or 1 for endoscopy) at week 12. A multiple testing procedure was used that began with the 600-mg dose group, and any nonsignificant comparison result ended the formal statistical testing procedure. RESULTS: At week 12, 15.9% (P = .066), 22.6% (P = .004), and 11.5% (P = .142) of patients in the 50-mg, 200-mg, and 600-mg groups achieved clinical remission, respectively, compared with 4.8% of patients given placebo. The primary endpoint was not significant (comparison to 600 mg, P > .05). Clinical responses occurred in 41.3% (P = .014), 59.7% (P < .001), and 49.2% (P = .001) of patients in the 50-mg, 200-mg, and 600-mg groups, respectively, compared with 20.6% of patients given placebo. At week 52, 46.8% of patients given subcutaneous mirikizumab 200 mg every 4 weeks and 37.0% given subcutaneous mirikizumab 200 mg every 12 weeks were in clinical remission. CONCLUSIONS: In a randomized trial of patients with UC, mirikizumab was effective in inducing a clinical response after 12 weeks. Additional studies are required to determine the optimal dose for induction of remission. Mirikizumab showed durable efficacy throughout the maintenance period. Clinicaltrials.gov, Number NCT02589665.
引用
- Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2019. PMID: 31493397. doi:10.1053/j.gastro.2019.08.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。